BridgeBio Pharma, Inc. (BBIO) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 94.4% | -113.3% | -145.3% |
| 2024 | 98.3% | -267.2% | -241.4% |
| 2023 | 73.7% | -6528.8% | -6913.9% |
| 2022 | 95.6% | -659.6% | -619.7% |
| 2021 | 95.5% | -827.1% | -806.9% |
Download Data
Export BBIO earnings history in CSV or JSON format
Free sign-in required to download data
BridgeBio Pharma, Inc. (BBIO) Earnings Overview
As of March 2, 2026, BridgeBio Pharma, Inc. (BBIO) reported trailing twelve-month net income of -$729M, reflecting -0.3% year-over-year growth. The company earned $-3.70 per diluted share over the past four quarters, with a net profit margin of -1.5%.
Looking at the long-term picture, BBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$31M in fiscal 2017.
BridgeBio Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), BBIO has outperformed on profitability metrics. Compare BBIO vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$729M | -36.1% | -$569M | $-3.79 | -145.3% | -113.3% |
| 2024 | -$536M | +16.7% | -$593M | $-2.88 | -241.4% | -267.2% |
| 2023 | -$643M | -33.7% | -$607M | $-3.95 | -6913.9% | -6528.8% |
| 2022 | -$481M | +14.5% | -$512M | $-3.35 | -619.7% | -659.6% |
| 2021 | -$563M | -25.4% | -$577M | $-3.90 | -806.9% | -827.1% |
| 2020 | -$449M | -72.3% | -$474M | $-4.10 | -5439.7% | -5752.0% |
| 2019 | -$260M | -99.2% | -$266M | $-2.48 | -642.1% | -656.4% |
| 2018 | -$131M | -327.8% | -$184M | $-1.42 | - | - |
| 2017 | -$31M | - | -$44M | $-0.33 | - | - |
See BBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBIO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BBIO vs AGIO
See how BBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BBIO growing earnings?
BBIO EPS of $-3.70 reflects slowing growth at -0.3%, below the 5-year CAGR of N/A. TTM net income is $-729M. Expansion rate has moderated.
What are BBIO's profit margins?
BridgeBio Pharma, Inc. net margin is -1.5%, with operating margin at -1.1%. Below-average margins reflect competitive or cost pressures.
How consistent are BBIO's earnings?
BBIO earnings data spans 2017-2025. The current earnings trend is -0.3% YoY. Historical data enables comparison across business cycles.